Premium
Rotavirus Disease and Its Prevention in Infants and Children
Author(s) -
Raebel Marsha A.,
Ou Brandon S.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.16.1279.30875
Subject(s) - rotavirus , environmental health , medicine , rotavirus vaccine , disease , immunization , developing country , economic cost , health care , pediatrics , economic growth , virology , immunology , economics , virus , neoclassical economics , pathology , antigen
Rotavirus disease causes immense morbidity and mortality in developing countries. In the United States, mortality is very rare, but the health care and societal costs of rotavirus‐related morbidity exceed one billion dollars annually. A new vaccine that prevents the illness recently was marketed in the United States. Economic issues surround national recommendations for its use. Economic, safety, and effectiveness issues will be resolved only with surveillance systems that document the effectiveness of immunization programs and their cost‐effectiveness.